Treatment with direct oral anticoagulant (DOAC) plus P2Y12 inhibitor (dual therapy) in adults with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) reduces bleeding risk compared with vitamin K antagonist plus aspirin and P2Y12 inhibitor (triple therapy), suggest a study.
Use of oral anticoagulation (OAC) among patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) is low, reveals a study. OAC use does not appear to reduce the risk of stroke or death and is even associated with higher risks of hospitalization for bleeding or intracranial haemorrhage.
Taking oestradiol therapy within 6 years after the start of menopause significantly delayed lipid plaque buildup in arterial walls — a leading cause of atherosclerosis, but such benefit was not seen when starting oestradiol a decade after menopause, reveals a secondary analysis of the ELITE* study presented at the recent EPI Lifestyle 2020 Scientific Sessions.
Treatment with inclisiran led to a significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients with atherosclerotic cardiovascular disease (ASCVD), according to two phase III randomized clinical trials.
Heart failure (HF) is a progressive condition where the heart is unable to pump enough blood to meet the body’s needs. Common causes of HF include ischaemic heart disease (IHD), hypertension, cardiomyopathy, diabetes and thyroid disorders. Patients with HF generally require lifelong treatment, but often ask if their medications may be stopped once their symptoms have improved. In this case study, Dato’ Dr Azmee Mohd Ghazi shares his clinical experience treating HF and the current evidence for HF therapy withdrawal.